Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Medical Genetics · GLS- and MSMO1-related metabolic disorders

The Biology Behind the Symptoms: Glutamate and Sterols

At a Glance

Changes in GLS can make glutamate signaling too active and may affect brain development, while MSMO1 deficiency disrupts cholesterol production and causes buildup of related fats. Both pathways may be linked to infantile cataracts, but red, scaly skin is more typical of MSMO1 deficiency.

When you are told your child has a rare metabolic condition, it can feel like learning a foreign language. To understand why these symptoms—like cataracts, skin issues, and developmental delays—happen together, we have to look at the “instruction manual” inside your child’s cells.

While the symptoms may look similar on the surface, they usually stem from one of two very different biological pathways: one involving a brain chemical called glutamate, and the other involving sterols, which are the building blocks of cholesterol. Do not change your child’s protein intake, feeding schedule, formulas, or supplements based on these chemical pathways without explicit instruction from a metabolic dietitian.

The Glutamate “Gas Pedal” (GLS Variant)

In some children, the issue is a variant in the GLS gene. This gene makes an enzyme called glutaminase. Normally, this enzyme acts to turn a chemical called glutamine into glutamate, which the brain uses to send signals [1].

In a gain-of-function variant, the enzyme becomes overactive. This happens through a specific type of mutation—often called a de novo mutation, meaning it happened for the first time in the child and was not inherited from the parents [2].

  • The Brake Failure: In these variants (specifically those labeled S482C or H461L), the enzyme exhibits abnormal regulation and reduced product inhibition [3][1].
  • Glutamate Overflow: This leads to an accumulation of glutamate in the brain. Because glutamate is “exciting” to brain cells, having too much can be excitotoxic, leading to developmental delays and seizures [2][4].
  • Glutamine Depletion: Because the enzyme is constantly using up glutamine to make glutamate, the levels of glutamine in the brain can become nearly undetectable [2].

Why the Eyes? (The GLS Connection)

In animal models like zebrafish, researchers have hypothesized that this chemical imbalance affects the lens of the eye. When glutamate levels are too high, it is proposed that it lowers the eye’s ability to clear out “trash” molecules called reactive oxygen species [2]. This “oxidative stress” damages the delicate proteins in the lens, causing them to clump together and form infantile cataracts [2]. This remains a proposed mechanism, not fully proven in humans.

The Cholesterol “Roadblock” (MSMO1 Deficiency)

In other cases, the symptoms are caused by a loss-of-function variant in the MSMO1 gene (also called SC4MOL). This is typically a biallelic condition, meaning the child inherited one non-working copy of the gene from each parent [5].

This gene is responsible for a C4-demethylation step in making cholesterol. Think of it like an assembly line where MSMO1 removes specific “parts” (called methyl groups) from a molecule [6][7].

  • The Roadblock: When this step is blocked, the assembly line stops. This leads to a shortage of finished cholesterol and a dangerous buildup of the unfinished parts, called C4-methylsterols [6][5].
  • Skin and Brain: Cholesterol is vital for building the “barrier” of the skin and the protective coating of brain cells. Without it, the skin becomes red and scaly (psoriasiform dermatitis), and the brain may not develop at the expected rate [5][8].

Why the Eyes? (The MSMO1 Connection)

The lens of the eye has one of the highest concentrations of cholesterol in the entire body. It needs a very specific mix of fats (lipids) to stay clear and flexible [9]. In MSMO1 deficiency, the lack of cholesterol and the buildup of the “unfinished” methylsterols change the structure of the lens membranes, causing them to turn cloudy very early in life [9][10].

Comparing the Two Pathways

Feature GLS Gain-of-Function MSMO1 Deficiency
Genetic Cause De novo (New in child) [2] Biallelic (From both parents) [5]
Primary Issue Too much glutamate [1] Too little cholesterol [6]
Main Mechanism Excitotoxicity (Over-active brain) [2] Sterol Accumulation (Toxic buildup) [5]
Lens Damage Oxidative stress (animal models) [2] Altered lipid membranes [9]
Skin Issues Less common/Not a primary feature Very common (red, scaly skin) [8]

Glossary

  • GLS: Glutaminase, the enzyme that produces glutamate.
  • MSMO1 / SC4MOL: Gene involved in cholesterol synthesis.
  • Sterol: A lipid molecule; cholesterol is a sterol.
  • Leukocoria: A white pupil reflex requiring urgent medical check.
  • Aphakia: The absence of the lens of the eye, typically after cataract surgery.
  • VUS: Variant of Uncertain Significance.
  • In Trans: Mutations on opposite chromosomes (inherited one from each parent).

Common questions in this guide

What is the difference between a GLS variant and MSMO1 deficiency?
A gain-of-function GLS variant can make glutaminase overactive, so the brain may have too much glutamate and too little glutamine. MSMO1 deficiency blocks a step in cholesterol production, leading to low cholesterol and buildup of C4-methylsterols. Both can be linked with early cataracts and developmental problems, but red, scaly skin is more typical of MSMO1 deficiency.
How could a GLS change affect my child’s brain and eyes?
An overactive GLS enzyme can increase glutamate, an excitatory brain chemical, and use up glutamine. Too much glutamate may overstimulate brain cells, contributing to developmental delay and seizures. The proposed link to infantile cataracts involves oxidative stress in the lens and has not been fully proven in humans.
Why does MSMO1 deficiency cause skin changes and cataracts?
MSMO1 normally helps make cholesterol. When it is not working, cholesterol can be low and C4-methylsterols can build up, affecting the skin barrier and the lens. This can lead to red, scaly skin and early clouding of the lens.
What does a de novo GLS variant mean for future children?
De novo means the variant arose for the first time in the child and was not inherited from either parent. A genetic counselor or medical geneticist can estimate the chance of recurrence after reviewing the child’s and parents’ test results, because rare parental mosaicism can affect risk.
Should I change my child’s diet or supplements because of glutamate or sterol results?
No changes to protein intake, feeding schedule, formula, or supplements should be made based only on these biological pathways. Ask your child’s metabolic dietitian or care team for specific instructions.
Are statins or special skin treatments proven for MSMO1 deficiency?
The page identifies lipid-rich skin treatments and statins as topics to discuss with the care team, not as routine treatments that families should start on their own. A metabolic specialist and dermatologist can explain whether any option is appropriate for your child.

Get notified when new evidence is published on infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (10)
  1. 1

    Structure and enzymology of glutaminase S482C and H461L variants associated with excess brain glutamate and neurological disease.

    Crane CS, McIssac TK, Milano SK, et al.

    The Journal of biological chemistry 2026; (302(6)):113091 doi:10.1016/j.jbc.2026.113091.

    PMID: 42055345
  2. 2

    GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay.

    Rumping L, Tessadori F, Pouwels PJW, et al.

    Human molecular genetics 2019; (28(1)):96-104 doi:10.1093/hmg/ddy330.

    PMID: 30239721
  3. 3

    Structure and enzymology of glutaminase mutants that disrupt glutamine-glutamate homeostasis and cause neurological disease.

    Crane CS, McIssac TK, Milano SK, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.09.14.674662.

    PMID: 41000630
  4. 4

    A second case of glutaminase hyperactivity: Expanding the phenotype with epilepsy.

    Rumping L, Pouwels PJW, Wolf NI, et al.

    JIMD reports 2023; (64(3)):217-222 doi:10.1002/jmd2.12359.

    PMID: 37151363
  5. 5

    A rare case of sterol-C4-methyl oxidase deficiency in a young Italian male: Biochemical and molecular characterization.

    Frisso G, Gelzo M, Procopio E, et al.

    Molecular genetics and metabolism 2017; (121(4)):329-335 doi:10.1016/j.ymgme.2017.06.013.

    PMID: 28673550
  6. 6

    Cholesterol synthesis enzyme SC4MOL is fine-tuned by sterols and targeted for degradation by the E3 ligase MARCHF6.

    Qian L, Scott NA, Capell-Hattam IM, et al.

    Journal of lipid research 2023; (64(5)):100362 doi:10.1016/j.jlr.2023.100362.

    PMID: 36958722
  7. 7

    [Role of sterol-C4-methyl oxidase-like in sterol synthesis].

    Zhnag R, Zang M, Lu J, et al.

    Sheng wu gong cheng xue bao = Chinese journal of biotechnology 2025; (41(11)):4111-4124 doi:10.13345/j.cjb.250443.

    PMID: 41457594
  8. 8

    MSMO1 deficiency: a potentially partially treatable, ultrarare neurodevelopmental disorder with psoriasiform dermatitis, alopecia and polydactyly.

    Tkemaladze T, Bratland E, Bregvadze K, et al.

    Clinical dysmorphology 2023; (32(3)):97-105 doi:10.1097/MCD.0000000000000461.

    PMID: 37195326
  9. 9

    Infantile Cataracts Associated with a Homozygous Missense MSMO1 Variant-Case Report and Literature Review.

    Hassas N, Drackley A, Ivanisevic J, et al.

    Reports (MDPI) 2026; (9(1)) doi:10.3390/reports9010045.

    PMID: 41718295
  10. 10

    Zebrafish models of skeletal dysplasia induced by cholesterol biosynthesis deficiency.

    Anderson RA, Schwalbach KT, Mui SR, et al.

    Disease models & mechanisms 2020; (13(6)) doi:10.1242/dmm.042549.

    PMID: 32430393

This page is for informational purposes only and does not constitute medical advice. Do not change your child’s diet, formula, supplements, or treatment without guidance from the child’s metabolic care team.